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1. INTRODUCTION
This chapter was originally intended to cover both amyotrophic lateral scle-
rosis (ALS) and multiple sclerosis, but we will concentrate on ALS. There are
nonetheless  several  reports  from  the  literature  that  ionotropic  glutamate
receptor antagonists have beneficial effects in animal models of multiple scle-
rosis (1,7,14,58,71,109) and this could develop into a very promising thera-
peutic area in the future. The interested reader is referred to the following
review (59). However, the evidence for involvement of disturbances in the
glutamatergic system in ALS is already convincing and has led to the use of
the glutamate release inhibitor riluzole in the treatment of this disease. As
such, we felt that a book on the therapeutic potential of ionotropic glutamate
receptor antagonists and modulators would be incomplete without a chapter
on this disease. 
2. RATIONALE
ALS, commonly called Lou Gehrig’s disease, is a devastating neurological dis-
order characterized by selective upper and lower somatic, but not autonomic,
motor neurone degeneration leading to paralysis and eventually death. The
diagnosis of ALS requires the presence of both upper and lower motor neu-
rone degeneration and progressive motor dysfunction. ALS occurs in 1 to 2.5
cases per 100,000 population, affects more men than women, and is most
commonly diagnosed in middle age. Other functions such as intellectual abil-
ities and sensory perception are preserved. At advanced stages patients become
completely disabled, often requiring ventilatory support and feeding by gas-
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(ALS)trostomy. Death usually occurs within five years of diagnosis and is attributed
to respiratory failure or cachexia.
In familial ALS, 20% of the cases are associated with mutations of the cop-
per/zinc superoxide dismutase-1 (SOD-1) gene (73,75,83, 87). However, the
aetiology of sporadic ALS (90% of patients) remains elusive in spite of intense
research. Several theories regarding the pathogenesis of ALS have emerged
including glutamate excitotoxicity, free radical oxidative stress, neurofilament
accumulation, and autoimmunity.
The role of the glutamatergic system in the pathology of ALS is well docu-
mented but existing literature is partially contradictory. This stems both from
post mortem, brain imaging and plasma/CSF studies in ALS patients and
observations in animal models.
2.1. Pathology
Over a decade ago, it was shown that the pattern of neuronal loss in the spinal
cord in patients suffering from ALS resembles that obtained after excitotoxic
lesions induced by kainate in animals (43). Injection of kainate to the spinal
cord produces damage to motor neurones while NMDA lesions affect main-
ly dorsal horn neurones (44). Similarly, short exposure to kainate in vitro
results in selective Ca2+-dependent death of motor neurones expressing Ca2+-
permeant AMPA receptors, whilst dorsal horn neurones are unaffected (102).
α -motor neurones in organotypic cultures of rat spinal cord are considerably
more sensitive to kainate and quisqualate than to NMDA toxicity (81). This
selective motor neurone death is insensitive to inhibitors of voltage-activated
sodium channels (VASCs) and voltage-activated calcium channels (VACCs)
but is completely blocked by the AMPA receptor antagonists LY300164 and
Joro spider toxin (selective for Ca2+ permeant receptors - see below) (102).
This suggests non-NMDA (AMPA or kainate) receptor involvement. 
CSF from ALS patients seems to contain factors with agonistic properties at
AMPA receptors (23). Similarly, the number of Fos-like immunoreactivity
positive neurones in organotypic cultures of rat lumbar spinal cord was sig-
nificantly increased in the dorsal horn by addition of CSF from ALS patients
as well as by glutamate (100 µM). These effects were, in both cases, blocked
by (+)MK-801 and not by CNQX (55), indicating a predominant role of
NMDA receptors.
A possible link between excitotoxicity and autoimmune deficiency in ALS
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injected i.p. to rats 24 hrs later produces an increase in glutamate content in
the CSF (50,84).
2.2. Serum / CSF Amino Acids
As in other proposed chronic excitotoxic diseases, studies on changes in amino
acid levels in ALS are strongly divergent, and there are often contradictions
between brain imaging, CSF and plasma / serum levels, even within the same
study (65,72). If, as reviewed below, glutamate transporters are involved in the
pathogenesis, then it should be stressed that local synaptic concentrations of
excitatory amino acids can be expected to be very different from those assessed
with such techniques. 
In ALS patients with a mild course of the disease, serum glutamate and
aspartate content was either normal or slightly decreased, whereas in severely
progressing cases serum glutamate and aspartate levels were increased, both
effects being accompanied by the opposite changes in glycine concentration
(65). Analysis of CSF concentrations in 377 ALS patients revealed the exis-
tence of two groups, one with normal glutamate concentrations and one with
high glutamate concentrations (41% of ALS patients) which correlated with
a spinal onset of the disease, more impaired limb function, and a higher rate
of muscle deterioration (90). Similar differences were not seen in 88 other
neurological patients and 18 normal controls. Another study also showed cor-
relation between CSF glutamate content and functional impairment assessed
with transcranial magnetic resonance stimulation in ALS patients (2).
Proton magnetic resonance spectroscopic imaging of the medulla of ALS
patients revealed increased glutamate and glutamine and reduced N-acetyl-
aspartate  (NAA)  and  N-acetyl-aspartyl-glutamate  (NAAG)  content  (69).
Bulbar symptoms correlated with the changes in glutamate and glutamine but
not NAA and NAAG, consistent with the hypothesis of glutamate excitotox-
icity in the pathology of ALS (69). In contrast, others have reported that
motor cortical and brainstem reductions in NAA content assessed by MRS
correlated with the severity of upper motor neurone abnormalities (17). 
In the precentral gyrus of ALS patients, glutamate and NAA concentrations
were actually decreased, whereas choline and myoinositol concentrations were
increased as assessed with localized proton MR spectroscopy (15). Decreased
contents of glutamate and aspartate as well as collagen-associated amino acids
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the lateral corticospinal tract and the anterior horn of ALS patients (67).
Significant reductions in glutamate and aspartate content and increases in
reactive astrocytes (i.e., staining with glial fibrillary acidic protein, GFAP)
have also been observed in the ALS spinal cord obtained at autopsy (64).
These biochemical results corresponded well to pathomorphological neuronal
degenerative loss and reactive proliferation of astroglial components in the
ALS spinal cord tissue. However, these authors also stressed that their results
may only reflect the final pathological and biochemical outcomes of ALS, and
give little insight into factors underlying progression of the disease (64).
Another study, with proton magnetic resonance spectroscopy in patients
with ALS, in contrast, revealed no differences in glutamate/ phosphocreatine
or glutamine/phosphocreatine ratios but decreased NAA which was proposed
to reflect neuronal loss or dysfunction (13).
Elevation of taurine has been found in the CNS of ALS patients (54).
Taurine is the final product of the metabolic pathway of sulphur amino acids
(36) and suggests that intermediate excitatory SAAs could also be increased.
Homocysteic acid (HCA) and homocysteine sulphinic acid (HCSA) cause
“apoptotic-like” cell death in rat cortical cell cultures (100). This may be relat-
ed to the fact that cysteine sulphinic acid (CSA) and cysteic acid (CA) potent-
ly inhibit glutamate uptake in synaptosomal fractions from rat cortex (49).
Inhibition of high-affinity glutamate transporters by excitatory SAAs, espe-
cially CSA and CA, may therefore also be involved in the pathogenesis of ALS.
2.3. EAAT-2
The most widely accepted deficit in sporadic ALS patients seems to be a loss
of glial glutamate uptake (excitatory amino acid transporter 2, EAAT-2, GLT-
1) evidenced by alteration in protein levels but not changes in mRNA in the
spinal cord (37,77,78,82). Results in the motor cortex are less consistent, indi-
cating that glutamate transporter pathology in this disease may also be a more
complex phenomenon than previously recognized (77,78,82; c.f. 37). A 43%
reduction of high- affinity glutamate uptake rate was also observed in platelets
from patients with ALS, compared with normal controls and with patients
suffering from different chronic neurological diseases, suggesting a systemic
impairment of glutamate uptake in ALS (34).
Two studies showed that mutations in the EAAT2 gene in sporadic ALS are
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EAAT2 in more than 50% of sporadic ALS cases (4,45). Thus, mechanisms
other than mutations within the coding region of EAAT2 must be responsi-
ble for the low levels of EAAT2 in sporadic ALS. Another study suggested that
the loss of EAAT2 is due to multiple aberrant mRNA restricted to neu-
ropathologically affected areas (53). These aberrant mRNAs were proposed to
result  from  processing  errors  including  intron-retention  (EAAT2/Int)  and
exon-skipping  (EAAT2/C1)  which  may  then  undergo  rapid  degradation
and/or produce a dominant negative effect on normal EAAT2, resulting in
loss  of  protein  and  activity.  Aberrant  EAAT2  mRNA  species  were  also
detectable in the CSF of ALS patients, early in the disease, and were therefore
proposed to be of diagnostic utility (53).
However, another study was unable to confirm a significant correlation
between the presence of (EAAT2/C1; EAAT2/Int) and three novel aberrant
mRNAs (EAAT2/C2-4) in the motor cortex and ALS pathology (61). Other
studies confirmed the presence of similar splice variants in different brain
regions of ALS patients, but they were also present in the brains of patients
with Alzheimer´s disease, Lewy body dementia, and even in normal controls,
albeit at lower levels (35,41).
As such, the cause of the decreased expression of EAAT2 in the spinal cord
of ALS patients is still a matter of heavy debate. Whatever the mechanism,
changes in EAAT2 expression probably results in an increase in synaptic glu-
tamate concentrations leading to excitotoxicity (76,94). This is clearly illus-
trated by the fact that administration of glutamate transporter antisense in rats
leads to a motor syndrome which includes hindlimb paresis (76). In fact, after
glutamate loading (60 mg/kg, p.o.) there is a significantly higher increase in
glutamate and aspartate levels in plasma in ALS patients than in matched con-
trols (38).
2.3.1. Oxidative Stress
Oxidative reactions seem to be involved in disease processes in the spinal cord
of sporadic ALS patients, while there is less evidence for increased oxidative
damage in familial ALS (86). It is known that biological oxidants reduce glu-
tamate transporter function and could thereby contribute to build-up of neu-
rotoxic extracellular glutamate levels (68,97). For example, nitric oxide (NO)
inhibits glutamate transport, and levels of its stable metabolites (NO2
- and
Amyotrophic Lateral Sclerosis 543NO3
-) were found to be higher in the serum but not CSF of male sporadic
ALS patients, potentially implicating NO in the pathogenesis of ALS, direct-
ly or indirectly, and in a sexually dimorphic manner (95). Mutations in SOD-
1 (see later) not only reduce the capacity to detoxify superoxide, but can actu-
ally catalyse the formation of more deleterious oxidants, such as peroxynitrite
(9) and hydrogen peroxide (112). Specific “redox-sensing” elements, consist-
ing of cysteine residues, have been identified in the structures of at least three
transporter subtypes (EAAT-1, EAAT-2 and EAAT-3) (97,98).
2.4. Ca2+ Permeable AMPA Receptors
One of the crucial questions is why certain motor neurone populations are
particularly prone to death in ALS. Although there is no clear cut answer to
this question, one of the possibilities is weak Ca2+ buffering capacity con-
nected with lowered levels of cytoplasmic proteins responsible for such buffer-
ing, such as parvalbumin and calbindin (5,48,79,83,84).
Another explanation is that spinal human motor neurones show low expres-
sion of the GluR2 subunit, making AMPA receptors permeable to Ca2+ which
renders them more vulnerable to excitotoxicity (83,85,93,113). Also impor-
tant is the fact that editing of mRNA for the GluR2 subunit of AMPA recep-
tors is reduced in the ventral grey matter of patients with ALS, since receptors
expressing unedited GluR2 also show very high Ca2+ permeability (93). These
receptors are also permeant for Zn2+ which may play an additional intracellu-
lar role in triggering pathological changes (56,111,114).
Other studies in the rat have been unable to reproduce these findings and
have therefore attributed increased vulnerability to the greater AMPA recep-
tor density in motor neurones, but it should be noted that they studied cul-
tured cells obtained from early embryonic tissue (103,104). It should howev-
er, also be stressed that other neurones expressing low levels of edited GluR2
such as forebrain GABAergic interneurones are less susceptible to glutamate
toxicity, indicating that both differences in Ca2+ buffering capacity and Ca2+
permeability may be important in determining the increased sensitivity of
motor neurones (21). Although transgenic mice with deficient Q/R-site edit-
ing of the of GluR2 subunit showed neurological deficits, no clear signs of
Ca2+-dependent motor neuronal death were observed (33). Similarly, a recent
in situ hybridization, RT-PCR and immunohistochemical study in normal
adult  rats,  showed  no  significant  difference  in  GluR2  mRNA  or  protein
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oculomotor nucleus) cranial motor nuclei (52). However, the presence of
mRNA alone is not sufficient to implicate incorporation into functional pro-
teins. Moreover, a recent immunohistochemical double-staining experiment
demonstrated that motor neurones expressing edited GluR2, also expressed
Ca2+-permeable AMPA receptors, indicating that GluR2 is excluded from a
subset of AMPA receptors in these cells (102).
2.5. NMDA Receptors
Most of the evidence presented above points to a primary involvement of
AMPA receptors in neurodegeneration in ALS. In fact, data on the NMDA
receptor role are scarce, and clinical evidence (see below) is rather discourag-
ing. There is however, a decrease in the NR1 subunit in ventral (but not dor-
sal) spinal cord of ALS patients and a decrease in glycine transporter (106).
NMDA receptor  expression  assessed  with  [3H]MK-801  binding  in  spinal
cord sections from patients who died of ALS was reduced, and this effect was
reversed by phorbol esters. Recent results indicate that abnormal levels or
activity of protein phosphatases, including calcineurin, may be involved in
this effect in ALS and may play some role in the pathogenesis of the disease
(107). The decrease in the glycine transporter could lead to enhanced glycine
levels and excessive positive modulation of NMDA receptors. In the spinal
cord a decrease of NR2A subunit expression (55-78%) has also been observed
(80). The question is whether these deficits are the cause of the neurodegen-
eration or rather should be interpreted as a secondary consequence of a loss of
neurones originally expressing these receptors.
There is evidence that abnormal phosphorylation of protein kinases may be
involved in the pathogenesis of ALS and could, for example, cause changes in
AMPA and NMDA receptor function. It is again unclear whether this is a pri-
mary cause, a secondary event, or a compensatory mechanism – for review see
(108).
The  neuronal  accumulation  of  phosphorylated  neurofilaments  (NFs)  in
ALS patients suggests an alteration of phosphorylation of NFs is also impor-
tant (30,73,105). In vitro studies in cultured rat cerebellar granule cells sug-
gest that exposure to a low concentration of glutamate enhances the phos-
phorylation of NFs, mainly via the AMPA receptor (6). It seems likely that
these changes are a consequence rather than the cause of the pathological
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2.6. Summary
Although the evidence presented above is partly contradictory, it nonetheless
makes the excitotoxic hypothesis of motor neurone cell death in ALS quite
attractive. Its seems clear that both a diminished function of glutamate trans-
porters such as EAAT2 and an increased susceptibility of motor neurones to
glutamate due to increased expression of Ca2+ permeant AMPA receptors are
important in the aetiology of both familial and sporadic ALS. Other potential
targets for therapeutic intervention such as intracellular Ca2+ binding pro-
teins, metabotropic glutamate receptors, growth factors and free radicals are
out of the scope of the present review.
2.7. Riluzole is a Glutamate Release Inhibitor
In spite of extensive studies, the precise mechanism of action of riluzole (RP
54274) remains elusive. Riluzole, clearly decreases the synaptic release of glu-
tamate and other neurotransmitters (19,22, 57,101) and this effect is proba-
bly  secondary  to  inhibition  of  voltage-activated  Na+ channels  (VASCs)
(27,115). Here we discuss the mechanism of action of riluzole in vitro as sup-
portive evidence for the role of glutamate in ALS. Later we shall discuss the
effects of this compound in animal models of this disease.
Although  at  first  sight  the  concentrations  of  riluzole  required  to  block
VASCs may seem to be too high (50-150 µM) it seems that it is far more
potent in retaining these channels in their inactivated state (i.e., riluzole shift-
ed  the  steady-state  inactivation  curve  towards  more  negative  values)  and
would therefore be predicted to be more effective following repetitive activa-
tion (89,116). 
Riluzole (100 and 300 µM) has been reported to be ineffective against volt-
age-activated Ca2+ channels (VACCs) (116), while others have shown that it
blocks N- and P/Q-type channels but not L-type VACCs in DRG cells, with
the rank order of efficacy P/Q- > N- >> L-type channels (42). The absolute
potency was similar to that at VASCs, and again, lower concentrations shift-
ed  steady-state  inactivation  curves  towards  more  negative  values  (42).
Moreover, another report on acutely isolated neurones from the adult rat neo-
cortex indicates that riluzole is a potent antagonist of both VASCs and VACCs
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At first sight it also seems that riluzole is inactive at the third major family
of voltage-activated channels (i.e., voltage-activated K+ channels) (VAKCs)
(116). However, although the amplitude of the peak outward current through
inwardly rectifying VAKCs was not changed by riluzole, the amplitude of the
late component was markedly decreased, albeit with low potency (IC50 = 88
µM). Moreover, a very recent report indicates that riluzole may actually be an
activator of TREK-1 and TRAAK, two members of a potentially very impor-
tant new structural family of mammalian background K+ channels with four
transmembrane domains and two pore regions (29). Riluzole activation of
TRAAK was sustained, whereas its activation of TREK-1 was transient, fol-
lowed by inhibition (29).
In summary, riluzole clearly interacts with a variety of voltage-activated
channels, and considering their molecular diversity, it will probably be quite
some time until the whole mechanism of action has been characterized.
Riluzole also inhibits NMDA mediated currents in Xenopus oocytes with
an IC50 of 18 µM, although binding studies failed to detect a direct interac-
tion with the NMDA receptor complex (27). This antagonism is therefore
probably not direct, but rather secondary to intracellular, possibly G-protein-
dependent processes.
Another recent finding indicates that riluzole not only decreases glutamate
release, but also enhances glutamate uptake. Thus, in rat spinal cord synapto-
somes, the rate of glutamate uptake was significantly increased in the presence
of 0.1 µM and 1.0 µM riluzole, but not at higher concentrations (8). Kinetic
analysis demonstrated that riluzole (0.1 µM) decreased the apparent Km by
21% and increased the Vmax by 31%. Glutamate uptake was also signifi-
cantly increased in spinal cord synaptosomes obtained from rats treated with
8 mg/kg (i.p.) of riluzole and sacrificed 4 hrs later. Again, these effects may
have been secondary to activation of G-proteins, because they were blocked
by cholera toxin (8).
Whatever the receptors / channels involved, riluzole (1-30 µM) attenuated
submaximal neuronal death induced by 24 hr exposure to 30 µM kainate or
NMDA, but not that by 100 µM NMDA, in cortical cultures (47). Riluzole
also  attenuated  non-excitotoxic  oxidative  injury  induced  by  exposure  to
FeCl3, in the presence of (+)MK-801 and CNQX. Riluzole reduced Fe3+-
induced lipid peroxidation and inhibited cytosolic phospholipase A(2), indi-
cating that riluzole has direct antioxidative actions. Exposure to higher con-
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ronal death in a caspase-sensitive manner (47).
3. STUDIES IN ANIMAL MODELS
3.1. SOD-1 Mutants
Although only about 2% of all ALS cases are linked to human SOD-1 muta-
tions (i.e., 1 in 2.5 million population), transgenic models based on this aber-
ation have recently caused a flurry of research in this area, probably partially
because of the dearth of alternative models (63). Moreover, it should be noted
that mechanistic consequences of this mutation are still not clear (e.g., sever-
al studies indicate that SOD-1 mutations found in ALS do not have a reduced
capacity to clear superoxide radical and that transgenic mice have, in fact, a
gain in overall activity due to the co-presence of wild type SOD-1) (63).
Conversely, some of these mutations might actually increase the formation of
other more deleterious oxidants (9,112). Whatever the mechanism, these mice
do show signs typical for ALS patients, and excitotoxicity seems to be impor-
tant  in  mediating  the  pathology.  Also,  therapeutic  approaches  that  seem
promising in ALS are also effective (for review, see 63). Moreover, it is assumed
that many of the secondary processes involved in execution of motor neuronal
damage will be the same in the two forms of ALS, because the clinical symp-
toms and pathology are essentially indistinguishable.
In these mice, ALS-like abnormalities develop at 3-4 months of age while
death occurs at 5-6 months. Some researchers have found a decrease in high
affinity Na+-dependent glutamate uptake between 120 and 150 days of age
(20).  Interestingly,  a  significant  decrease  in V-max  (-40%)  in  spinal  cord
synaptosomes was seen at 150 days (i.e., one  week before the animal’s death
at 157 days), and this corresponded to a fall in muscle strength. In SOD-1
(but not wild-type) mice mutants, oxidative reactions triggered by hydrogen
peroxide inactivate human glutamate transporter EAAT-2 (GLT-1) (99). This
supports  the  notion  that  in  SOD-1-linked  familial  ALS,  neuronal  death
occurs via an excitotoxic mechanism. In line with this, in SOD-1(G93A)
transgenic mice, NMDA- and L-trans-pyrrolidine-2,4-dicarboxylate (LTPD)-
stimulated cortical glutamate release were significantly higher, as evidenced by
in vivo microdialysis  and  NMR  spectroscopy  (3).  These  results  suggest
impaired glutamate transport in these transgenic mice. Creatine increased
548 Chris G. Parsons and Wojciech Danyszlongevity and motor performance of SOD-1(G93A) mice, and decreased glu-
tamate release, possibly, as suggested by the authors, through improved func-
tion of the glutamate transporter.
Others also observed a progressive decrease in immunoreactivity for the glial
glutamate transporter (EAAT-2) in the ventral, but not in the dorsal horn of
the lumbar spinal cord of transgenic mice carrying mutated human SOD-
1(G93A) (10). However, the decreases in EAAT-2 occurred after symptoms
had already appeared and was accompanied by increased GFAP levels, which
suggests that it was not a primary event leading to motor neurone loss. Similar
conclusions were also obtained recently by others (24).
Mice transgenic for the SOD-1(G85R) mutation, showed marked symp-
toms of ALS, characterized by an extremely rapid clinical progression, with-
out changes in SOD-1 activity. Initial indicators of disease were SOD-1 like
astrocytic  inclusions/aggregates  and  ubiquitin.  The  number  of  astrocytic
inclusions escalated markedly as the disease progressed, and this effect was
accompanied by a decrease in the glial glutamate transporter (GLT-1) which
might imply a role of excitotoxicity in these models. (18).
Glutamate acting via calcium-permeable AMPA/kainate receptors may be a
major  factor  determining  vulnerability  of  motor  neurones  obtained  from
SOD-1 mutants (G41R, G93A, or N139K) since CNQX and Joro spider
toxin prevented neuronal death (79). The authors concluded that the neuro-
toxicity in these mice is dependent upon Ca2+ entry triggered by glutamate
and that this maybe a major factor in the vulnerability of motor neurones in
ALS  (79).  According  to  Morrison  et  al.  (62) the  distribution  of  GluR2
immunoreactivity in the spinal cord in SOD-1 transgenic mice is not altered
and thus cannot be the cause of the selective vulnerability observed in these
mice and possibly in ALS patients.
Riluzole (24 or 44 mg/kg/day in diet) - the only drug registered as a disease
modifying agent for ALS - delayed the development of motor impairment and
prolonged life span in SOD-1 (G93A) transgenic mice (40). This emphasizes
the role of an overactive glutamatergic system in the mechanisms of progres-
sive neurodegeneration at least in SOD-1 mutation related familial cases of
ALS.
3.2. Spontaneous Mutations
One spontaneously occurring model used to test for potential therapeutic
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examined the effect of chronic administration of the NMDA glycine site
antagonist L-701,324 on the onset and course of neurological impairment in
this model (16). Motor deficits starting at 6 months of age were apparent, as
a loss of hindlimb reflex extension, impairment of balance, and later abnor-
malities in walking pattern. L-701,324 (10 mg/kg p.o. daily) given from 4 to
8 months of age did not affect the onset of symptoms or the rate of deterio-
ration of motor performance. This suggests a lack of NMDA receptor involve-
ment in the development of these abnormalities. In contrast, in the same
model chronic treatment with NBQX (8 mg/kg daily i.p.) for 3 weeks (start-
ing at age of 24 weeks) significantly improved the behavioural scores (60).
These findings suggest again that antagonism of non-NMDA receptors rather
than NMDA receptors may be a valuable treatment of ALS. 
Progressive motor neuropathy (PMN) is another model of progressive neu-
ropathy resembling some features of ALS (70). The mutation which is spon-
taneous, recessive and locates to chromosome 13 leads to early paralysis of
hind limbs (2-3 weeks of age) and 2-3 weeks later to loss of distal axons, fol-
lowed by death resulting from respiratory muscle paralysis at 6-7 weeks. Since
the progression of neurodegeneration is clearly faster than in SOD-1 trans-
genic mice, this model is less time consuming but its relevance to ALS pathol-
ogy needs to determined (28). PMN mice treated with riluzole (8 mg/kg/day
p.o.) showed delayed onset of paralysis and death (46). This treatment also
improved motor performance and electromyographic alterations at early dis-
ease stages.
A third spontaneous murine phenotype often used as a model of ALS is the
Wobbler mouse. However, this model does not show similar pathological
changes in the glutamatergic system to those seen in ALS patents or SOD-1
transgenic mice (96) and has, to our knowledge, not been used to test the
effects of riluzole.
4. CLINICAL STUDIES
Hence, the evidence given above is probably sufficient to consider glutamate
antagonists as plausible neuroprotective treatment of ALS. Unfortunately, the
majority of clinical trials with glutamate antagonists, to date, have not been
encouraging. Dextromethorphan (NMDA channel blocker) showed no bene-
fit (12,39). Similar negative results were obtained with the glutamate release
550 Chris G. Parsons and Wojciech Danyszinhibitor (GRI) lamotrigine which in a 1.5 year long double blind study in 67
patients, failed to demonstrate a significant effect on disease progression (32).
In contrast, riluzole (also a GRI) has been shown to have moderate efficacy
in ALS, mainly expressed as a prolongation of survival in two studies con-
taining together 1104 patients (11,51), but this has not been confirmed by
others (19). This agent (®Rilutek) has been registered as a neuroprotective
treatment for ALS in several countries.
In a small group of ALS patients the primary peak of the peristimulus time
histograms  of  voluntarily  activated  single  anterior  horn  motor  units  was
delayed in onset and prolonged in duration (31). This kind of finding has
prompted  several  small  open  studies  to  use  electrophysiological  surrogate
parameters to confirm the therapeutic efficacy of riluzole in ALS patients
(25,26,88,110). As an example, in 22 ALS patients deficits in the motor unit
number estimate and the size of the motor unit action potential in median
innervated thenar muscles were partially normalized following treatment with
riluzole (110). Riluzole was also shown to partially restore deficient transcra-
nial magnetic stimulation-induced paired-pulse inhibition (PPI) in the first of
4 consecutive 3-month periods of testing, but left paired-pulse facilitation
(PPF) unchanged (91). These findings were taken to substantiate the role of
anti glutamatergic effects of riluzole in ALS (91). However, others have found
that riluzole does not immediately influence intracortical excitability in ALS,
but interpreted this to indicate a delayed onset of riluzole’s influence on intra-
cortical excitability (88).
In a pharmacovigilance study, riluzole did induce adverse effects in half the
patients, the most frequent of which were gastrointestinal disturbances, hepa-
totoxicity and asthenia. Nonetheless, riluzole was classified as showing an
acceptable safety profile (74). There has also been a case report raising the pos-
sibility of a causal relationship between riluzole treatment and granulocytope-
nia (66).
5. CONCLUSIONS
The evidence for a role of excitotoxic processes in disease progression is quite
convincing for both familial and sporadic ALS. Diminished function of glu-
tamate transporters, oxidative stress and increased expression of Ca2+ perme-
ant AMPA receptors in motor neurones participate in the pathogenesis of this
disorder, whereas NMDA receptors seem not to be involved. The glutamate
Amyotrophic Lateral Sclerosis 551release inhibitor riluzole is moderately effective, both in the clinic and in ani-
mal models of ALS. This provides further impetus to develop more effective
agents targeting the glutamatergic system for the treatment of this rare, but
devastating disease.
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